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Abstract 
Although renal cell carcinoma (RCC) can metastasize to almost every organ, the most 
common metastatic sites are the lungs, abdomen, bones and brain. We present a rare 
case of a 72-year-old male with a large left RCC with simultaneous bilateral adrenal 
metastasis. In the process of surgical treatment, he underwent left radical nephrectomy 
with ipsilateral adrenalectomy. Due to the poor general condition of the patient, and also 
to prevent adrenal insufficiency, the right adrenal mass was preserved, without imposing 
any hazard to the patient. Systemic immunotherapy was initiated and the patient is still 
alive 1 year after surgery. 
 
Introduction 
Although renal cell carcinoma (RCC) can metastasize to almost every organ, the most 
common metastatic sites are the lungs, abdomen, bones and brain. The possibility of 
bilateral adrenal metastasis (BAM) is very low (<0.5%). The remote but existing risk of 
developing contralateral adrenal metastasis (CAM) after primary radical nephrectomy  
Case Rep Oncol 2010;3:372–379 
DOI: 10.1159/000321717 
Published online: 
October 19, 2010 
© 2010 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
373
supports the idea of sparing the adrenal gland in suitable patients who undergo radical 
nephrectomy. 
Case Presentation 
The patient is a 72-year-old Iranian man who was admitted due to a left renal mass. He complained 
of intermittent gross hematuria in the 6 months before admission. He revealed no history of medical 
disorders like hypertension or diabetes mellitus. No history of any previous surgery was found. He was 
an obese man with a body mass index of 28. On physical examination, vital signs were normal and, due 
to a fatty abdomen, no mass was detectable. No lower extremity edema, varicose veins or peripheral 
lymphadenopathies were noted. Hematological examination was normal. In the biochemistry 
evaluation, only a serum creatinine level of 1.7 mg/dl was noted. Liver function test was normal. Chest 
X-ray was unremarkable. In abdominal ultrasonography, a left renal mass of 14 × 8 × 6.5 cm with 
bilateral adrenal masses (each 4 × 5 cm) were reported. In abdominal magnetic resonance imaging 
(MRI), the reported mass with BAM was revealed (fig. 1, fig. 2, fig. 3, fig. 4, fig. 5). The clinical TNM 
stage of the patient was T3N1M1. The patient was scheduled for left radical nephrectomy. With midline 
abdominal incision, laparotomy was performed. Standard left radical nephrectomy with resection of the 
ipsilateral adrenal metastasis with splenectomy (due to adhesions) was performed. Due to the poor 
general condition of the patient, severe adhesion of the mass, its large size and more than 2,000 ml of 
bleeding, the resection of the CAM was postponed. The weight of the resected mass was 3,375 g. 
Postoperative condition of the patient was uneventful. Only a mild elevation of the serum creatinine 
level to 2.5 mg/dl was seen. He was discharged on the 4th postoperative day in good condition. 
Pathologic examination of the nephrectomy sample was positive for RCC with adrenal metastasis, clear 
cell type, Fuhrman nuclear grade 3. The greatest tumor diameter was 9.5 cm. The tumor extends 
through the renal capsule to the peri-renal adipose tissue. Invasion of the renal vein is seen without any 
lymph node involvement. Due to adrenal metastasis, tyrosine kinase inhibitors were the recommended 
first line of treatment, but due to financial constraints, the patient refused their use and we were 
obligated to prescribe immunotherapy as an every day intramuscular injection of α-interferon (5 million 
units) for 2 consecutive months, without any major systemic reactions. Due to unknown causes, the 
patient had proceeded to end stage renal disease 3 months after operation, and he underwent regular 
hemodialysis after that. Finally, he was alive at the end of the first year after operation. 
Discussion 
The behavior of RCC is unpredictable; metastasis may be found synchronously with 
the primary tumor or in various organs many years after treating the primary RCC [1], 
following routes of spread and patterns that are not yet fully understood. Adrenal 
metastasis is a good example, as it can be synchronous or metachronous to the renal 
neoplasm, ipsilateral, contralateral or bilateral, solitary or part of a diffuse metastatic 
disease. Direct extension of RCC to the adrenal gland is uncommon. Adrenal metastases 
may result from either antegrade hematogenous spread or antegrade venous spread, 
although neither has been proven [2]. Although RCC can metastasize to almost every 
organ, the most common metastatic sites are the lungs, abdomen, bones and brain [3]. In 
addition to being able to metastasize to numerous different organs, RCC can recur or 
metastasize many years after resection of the primary tumor [4].  
Whereas metastasis of RCC to different sites is not uncommon, CAM is rare. In one 
autopsy study of >400 patients who had undergone nephrectomy for RCC, the 
contralateral adrenal gland was the sole site of metastatic involvement in only 2.5% [3]. In 
another retrospective study of a large series [5], 610 radical nephrectomy cases were 
studied. The incidence of CAM was 1.1% (7/610 patients), while the incidence of 
ipsilateral metastasis was 3.4%. In 3 of 7 cases (0.5%), BAM occurred simultaneously with  
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primary RCC in the kidney. In another study by Antonelli et al. [6], in over 1,179 patients 
the incidence of adrenal metastasis was 3.7%. In particular, the metastasis was 
synchronous in 2.7%, metachronous in 1%, ipsilateral in 1.9%, contralateral in 1.5%, and 
bilateral in 0.2% (2/914) of patients. The histological subtype of the adrenal metastasis 
was always concordant with that of the renal neoplasm. We postponed contralateral 
adrenalectomy due to the poor general condition of the patient at the time of surgery and 
also the fear of adrenal insufficiency, without increasing any risk of bilateral adrenal 
insufficiency to the patient. There were no differences in survival between patients with 
synchronous or metachronous appearance of adrenal metastasis, or between those with a 
uni-, contra- or bilateral metastasis [6]. Plawner [7] showed that the 5-year survival of 
patients operated on for asynchronous solitary RCC metastases to the contralateral 
adrenal gland was lower than that for patients with synchronous adrenal metastases, 
namely 20 and 40%, respectively. Patients in whom the contralateral gland is affected are 
dependent on hormone replacement following bilateral adrenal removal. The post-
adrenalectomy state created is associated with occasional morbidity and, perhaps, even 
mortality due to acute adrenal insufficiency [8]. Although hormone replacement therapy 
does not place a burden on young patients, it may become more relevant in later life when 
compliance becomes relatively poor [9]. The remote but existing risk of developing CAM 
after primary radical nephrectomy supports the idea of sparing the adrenal gland in 
suitable patients who undergo radical nephrectomy. In a prospective study, ipsilateral 
adrenal involvement (IADI) during radical nephrectomy was reported in 2% of cases [10]. 
Thus, the need for routine adrenalectomy during radical nephrectomy has been 
questioned, especially because the risk of an ipsilateral tumor developing after adrenal-
sparing nephrectomy is low [10]. 
Some patients benefit from contralateral adrenalectomy for metastatic RCC, and 
previously published experience also indicates that the surgical treatment of contralateral 
RCC metastasis is worthwhile in selected patients [11, 12]. The available information on 
the outcome of the surgical treatment of metastatic RCC to the contralateral adrenal 
gland is limited and incomplete [13]. Adjuvant treatment may improve the outcome. 
Patients with IADI had significantly larger primary tumors, higher pT stages and 
histologic grades, and higher percentages of upper pole involvement, microvascular 
invasion, spindel-cell-type tumors, lymph node metastasis (LNM), and distant metastasis 
(DM) outside the ipsilateral adrenal gland (IAd) than control patients [14]. Multivariate 
analysis revealed that tumor size greater than 5.5 cm, pT stage of 3 or higher, LNM, and 
DM outside IAd, but not upper pole involvement, were significant predictors of IADI 
[14]. In the Moudouni et al. study [15] on 15 patients with adrenal involvement in RCC, 
tumor stage correlated with probability of adrenal spread, with T3–4 and T1–2 
accounting for 13.4 and 0.9% of cases, respectively. Upper pole intrarenal RCC was most 
likely to spread with local extension to the adrenal gland, representing 53.3% of adrenal 
involvement. 
In contrast, multifocal, lower pole and mid region RCC tumors metastasized 
hematogenously, representing 21.4, 7 and 14% of adrenal metastasis, respectively. The 
morbidity of adrenalectomy is minimal except in those patients with synchronous CAM 
in whom the impact of adrenal insufficiency can be devastating. Disease-specific and 
overall survival of those undergoing radical nephrectomy, with or without adrenalectomy, 
are similar. The survival of patients with widespread metastatic disease is historically poor 
regardless of whether adrenalectomy is performed. There is evidence for a survival  
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advantage in patients with isolated adrenal metastasis, although this group comprises no 
more than 2% of those undergoing surgery for renal tumors [16]. 
On the basis of the study by Onishi et al. [17], patients who underwent the operation 
on the contralateral adrenal gland showed an unfavorable survival. Regarding the 
combination treatment with surgery, patients who received the interferon and 
interleukin-2 treatment showed a favorable survival. Several studies suggest that 
metastatic RCC (not by direct extension) in the IAd should be regarded as stage m+ (DM) 
and that the need and benefit of ipsilateral adrenalectomy during surgery for RCC are 
extremely limited [18, 19]. On the basis of the Yokoyama and Tanaka study [20], 
unilateral adrenalectomy might cause an irreversible impairment of the reserve of 
adrenocortical function, so unconditional ipsilateral adrenalectomy with radical 
nephrectomy for RCC should be avoidable, and thus preserve the reserve of 
adrenocortical function, as preoperative imaging, especially thin-slice multidetector 
helical computed tomography, can detect adrenal involvement with RCC in most cases. 
Conclusion 
In a prospective study, IADI during radical nephrectomy was reported in 2% of cases 
[10]. Thus, the need for routine adrenalectomy during radical nephrectomy has been 
questioned, especially because the risk of an ipsilateral tumor developing after adrenal-
sparing nephrectomy is low [10]. Sparing the IAd in radical nephrectomy would avoid the 
risk of adrenal insufficiency if the development of a tumor necessitates removing the 
contralateral gland, either at the time of nephrectomy or later [13]. Furthermore, the 
metastatic organs and the application of cytokines must be considered in the treatment of 
advanced RCC. In spite of general advise about the removal of adrenal masses (especially 
metachronous ones) we preserved the right adrenal mass to prevent the need for 
glucocorticoid and mineralocorticoid substitution therapy and to decrease the surgical 
risk for the patient. Furthermore, with initiation of post-surgical interferon therapy, the 
expected prognosis of the patient did not change. 
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Fig. 1. MRI of the abdomen. BAM is evident. 
 
 
 
Fig. 2. MRI of the abdomen. BAM is evident. 
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Fig. 3. Abdominal MRI, the left renal mass is evident. 
 
 
 
Fig. 4. Abdominal MRI, the left renal mass is evident. 
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Fig. 5. Abdominal MRI, the left renal mass is evident.. 
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